Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.

Autor:	Perroud HA; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.; National Scientific & Technological Research Council (CONICET), Rosario, Argentina., Alasino CM; Institute of Oncology of Rosario, Rosario, Argentina., Rico MJ; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.; National Scientific & Technological Research Council (CONICET), Rosario, Argentina., Queralt F; Institute of Oncology of Rosario, Rosario, Argentina., Pezzotto SM; Institute of Immunology, School of Medical Sciences, National University of Rosario, Rosario, Argentina.; Research Council of the National University of Rosario (CIUNR), Rosario, Argentina., Rozados VR; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina., Scharovsky OG; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.; Research Council of the National University of Rosario (CIUNR), Rosario, Argentina.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2016 May; Vol. 12 (10), pp. 1233-42. Date of Electronic Publication: 2016 Mar 07.
DOI:	10.2217/fon-2016-0075
Abstrakt:	Aim: The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib. Material & Methods: Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET). Results: A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional well-being and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it. Conclusion: Patients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment. Competing Interests: Financial & competing interests disclosureThis work was supported by Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT; grant number: PICT 2006/1908 to OG Scharovsky, VR Rozados, SM Pezzotto and CM Alasino). The National Cancer Institute at the NIH grants for doctoral fellows to HA Perroud. HA Perroud is a fellow of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu